Assistant Professor of Neuro-Oncology, MD Anderson Cancer Center. Tweets are my own.
Houston, TX
Joined March 2020
- Tweets100
- Following258
- Followers249
- Likes204
Nazanin Majd, MD, PhD retweeted
Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. mdanderson.org/patients-fami… #endcancer @MDAndersonNews
Nazanin Majd, MD, PhD retweeted
Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. @MDAndersonNews @NeuroNews01
Nazanin Majd, MD, PhD retweeted
Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial clinicaltrials.gov/study/NCT…. @MDAndersonNews #endcancer
Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial clinicaltrials.gov/study/NCT…. @MDAndersonNews #endcancer
Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. @MDAndersonNews @NeuroNews01
Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. mdanderson.org/patients-fami… #endcancer @MDAndersonNews
congratulations! very well deserved!
The @MDAndersonNews Neuro-Oncology department is thrilled to announce the promotion of @ChetnaWathoo, M.D., to Associate Director, Research Planning & Development. Dr. Wathoo’s ongoing contributions through leadership, mentorship & innovation are vital in our goal to #EndCancer. #BTAM
Nazanin Majd, MD, PhD retweeted
DDR 🤴!!! The Taylor Swift of Oncology!!! The man the myth……………Tim Yap!! @MDAndersonNews #ASCO24
Our newly activated trial is specifically designed for patients with oligodendroglioma (CIC mutated) and NF1-associated gliomas clinicaltrials.gov/ct2/show/…. Excited to announce this unique trial and accrue patients! #endcancer, @MDAndersonNews
It was my honor and a privilege to present the highlights of CNS tumors at #ASCO2023! Specially, highlighting the historical study by Dr. Mellinghoff and colleagues. nejm.org/doi/full/10.1056/NE…. Thank you ASCO organizers! @MDAndersonNews
Great honor to see Dr. Tanner and Dr. Yung @DrAlfredYung at #ASCO23!
This Post is from a suspended account. Learn more
Nazanin Majd, MD, PhD retweeted
The just-announced U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization represents a stunning reversal of precedent that inserts government into the personal lives and health care of Americans. nej.md/3Aa5cKe
Two of my favorite leaders committed to #endcancer! You are our source of inspiration! @DrAlfredYung , @MDAndersonNews
This Post is from an account that no longer exists. Learn more
Nazanin Majd, MD, PhD retweeted
To help reduce your cancer risk, aim for at least 150 minutes of moderate activity each week.
Watch to see ideas for getting active. #HealthAndWellness #EndCancer
Enjoyed reading this article by my amazing colleague and friend, @AshleyAaroe. Our field is lucky to have you as our patients’ advocate! #neurology, #braintumor, @MDAndersonNews neurologylive.com/view/neuro…
Congratulations! Your proud sister and mentee! ❤️@majdzadehr
After 15 years of intensive work, having +300 articles in PubMed, including prestigious journals: this is my favourite one: >3 years of work with a large group of researchers, community representatives, policymakers and managers. It has a video: see it
health-policy-systems.biomed…
Agree! This is a great resource for our patients! #BrainTumor #PatientCare
We all know about @NCCN guidelines for clinical practice, but this massive patient information summary for glioma is news to me! Are other #neurologists and #neurooncs using this resource (or do you prefer your own)
nccn.org/patients/guidelines…
Our updated Immunotherapy for Neuro-Oncology chapter is now available online! @MDAndersonNews Soecial thanks to @J_deGrootMD, Pushan Dasgupta, @ANaingMD, @HajjarJoud: pubmed.ncbi.nlm.nih.gov/3497…
Congratulations! @HTawbi_MD and team! @MDAndersonNews Treatment advances in melanoma inspire all oncologists! #EndCancer
On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.1056/NE…
“Apart from hope’s fundamental role in healing,giving hope is one of the most beautiful acts of kindness.True,there is always the danger that the hope given may be unrealistic.But just as a bit of light dissipates alot of darkness,so can a bit of hope ameliorate a lot of despair”
Because of the overwhelming interest in this special article by Dr. Daniel Drubach, who so eloquently describes his experiences as both #neurologist and patient with #dementia with Lewy bodies, we've made the article available to all at continpub.com/Twilight. @AANMember
